26
Mar

Hell hath no fury as a disappointed investor who bet wrong on a biotech catalyst. The execs at Exelixis got a three-course serving of that anger this morning as its stock went into a 35% nose dive–after the biotech announced that its interim analysis was complete and the Phase III prostate cancer study for cabozantinib would go to its conclusion.

…read more

Source: Exelixis’ shares flogged after lead drug disappoints at interim PhIII point

    

0 No comments